1. Home
  2. TLS vs ACIU Comparison

TLS vs ACIU Comparison

Compare TLS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telos Corporation

TLS

Telos Corporation

HOLD

Current Price

$5.18

Market Cap

463.8M

Sector

Technology

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.13

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLS
ACIU
Founded
1969
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.8M
213.3M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
TLS
ACIU
Price
$5.18
$3.13
Analyst Decision
Buy
Strong Buy
Analyst Count
5
2
Target Price
$7.75
$10.00
AVG Volume (30 Days)
1.0M
1.4M
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$144,400,000.00
$5,482,957.00
Revenue This Year
$52.27
N/A
Revenue Next Year
$20.44
$644.42
P/E Ratio
N/A
N/A
Revenue Growth
17.44
N/A
52 Week Low
$1.83
$1.43
52 Week High
$8.36
$4.00

Technical Indicators

Market Signals
Indicator
TLS
ACIU
Relative Strength Index (RSI) 39.52 51.89
Support Level $4.97 $2.87
Resistance Level $5.85 $3.21
Average True Range (ATR) 0.33 0.29
MACD -0.01 0.02
Stochastic Oscillator 15.40 44.05

Price Performance

Historical Comparison
TLS
ACIU

About TLS Telos Corporation

Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: